Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

The role of autophagy in hepatitis B virus infection and its research advances

The role of HBV-induced autophagy in HBV replication and HBV related-HCC

Cellular Immune Response In Patients With Chronic Hepatitis B Virus Infection

Immune Response of TLRs Mediated Anti-Hepatitis B Virus

Cytokines and Chemokines in HBV Infection

Relationship betwe en autophagy and hepatitis virus infection

Role of Autophagy in the Ubiquitinated Hepatitis B Virus Core Antigen Enhancing Dendritic Cell Function.

New advances in drug therapy of chronic hepatitis B infection

Focus on Dysregulated Adaptive Immunity in Chronic Hepatitis B: A Promising Direction for Immunotherapy

Interconnection of cellular autophagy and endosomal vesicle trafficking and its role in hepatitis B virus replication and release

Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation.

The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy

Subversion of Cellular Autophagy Machinery by Hepatitis B Virus for Viral Envelopment

Hmgb1-Induced Autophagy: A New Pathway to Maintain Treg Function During Chronic Hepatitis B Virus Infection

Hepatitis B virus dampens autophagy maturation via negative regulation of Rab7 expression.

Function and autophagy of monocyte-derived dendritic cells is affected by hepatitis B virus infection

Immunopathogenesis and immunotherapy of chronic hepatitis B virus infections

Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity

Plasmacytoid dendritic cell function and pathogenesis of chronic viral hepatitis B

Current trends and advances in antiviral therapy for chronic hepatitis B

Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies